178 related articles for article (PubMed ID: 28081538)
21. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
Fu Y; Li H
Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
[TBL] [Abstract][Full Text] [Related]
22. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
23. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression.
Eniu DT; Romanciuc F; Moraru C; Goidescu I; Eniu D; Staicu A; Rachieriu C; Buiga R; Socaciu C
Scand J Clin Lab Invest; 2019; 79(1-2):17-24. PubMed ID: 30880483
[TBL] [Abstract][Full Text] [Related]
24. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
Morrell S; Taylor R; Roder D; Robson B; Gregory M; Craig K
Br J Cancer; 2017 Mar; 116(6):828-839. PubMed ID: 28183141
[TBL] [Abstract][Full Text] [Related]
25. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.
Kashyap D; Kaur H
Life Sci; 2020 Apr; 246():117417. PubMed ID: 32044304
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Li P; He Q; Luo C; Qian L
Int J Clin Exp Pathol; 2015; 8(1):660-4. PubMed ID: 25755760
[TBL] [Abstract][Full Text] [Related]
27. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
[TBL] [Abstract][Full Text] [Related]
28. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer.
Liu Y; Liao Y; Xiang L; Jiang K; Li S; Huangfu M; Sun S
Int J Clin Oncol; 2017 Apr; 22(2):291-296. PubMed ID: 27778118
[TBL] [Abstract][Full Text] [Related]
29. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
Marks JR; Anderson KS; Engstrom P; Godwin AK; Esserman LJ; Longton G; Iversen ES; Mathew A; Patriotis C; Pepe MS
Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):435-41. PubMed ID: 25471344
[TBL] [Abstract][Full Text] [Related]
30. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer?
Velaiutham S; Taib NA; Ng KL; Yoong BK; Yip CH
Asian Pac J Cancer Prev; 2008; 9(3):445-8. PubMed ID: 18990019
[TBL] [Abstract][Full Text] [Related]
31. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
32. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
33. Blood-based protein biomarkers in breast cancer.
Núñez C
Clin Chim Acta; 2019 Mar; 490():113-127. PubMed ID: 30597138
[TBL] [Abstract][Full Text] [Related]
34. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
[TBL] [Abstract][Full Text] [Related]
35. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
37. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
38. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
39. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
40. Mode of detection: an independent prognostic factor for women with breast cancer.
Hofvind S; Holen Å; Román M; Sebuødegård S; Puig-Vives M; Akslen L
J Med Screen; 2016 Jun; 23(2):89-97. PubMed ID: 26582492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]